EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 271 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR Treatment with Encorafenib Plus Cetuximab Plus FOLFIRI Improves Outcomes in Patients with BRAF V600E-mutated mCRC FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma How Decades of NCI Support Led to Groundbreaking Discoveries: The Story of Immune Checkpoint Inhibitors MOST POPULAR Surgeons Use Tissue From Cancer Survivor’s Love Handles For Rare Type... February 27, 2020 Spotlight On: Occupational Therapists in Cancer Care November 4, 2021 ESMO Breast Cancer 2024, 15-17 May, Berlin, Germany May 8, 2024 Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent... March 5, 2026 Load more HOT NEWS How People With Cancer Can Benefit From Online Therapy The Best And Worst Face Masks For COVID-19, Plus Face Masks... After Breast Cancer Diagnosis, Technology Professor Teaches Computers to Read Mammograms Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’
